taking a specialty drug product from home to a hospital outpatient clinic or inpatient setting for administration, a practice known as "brown bagging, " raises concerns about product integrity and institutional liability. An institution's finances, tolerance for liability, and ability to skillfully manage the processes involved often determine its choice between an approach that prohibits brown bagging but is costly and one that permits the practice under certain conditions and is less costly. The recent shift from a traditional supply chain model to a specialty pharmacy supply chain model for high-cost pharmaceuticals has the potential to increase pharmaceutical costs for health systems. A dialogue is needed between health-system pharmacists and group purchasing organizations to address the latter's role in mitigating the financial implications of this change and to help clarify the safety issues. Some health plans have shifted part of the cost of expensive drugs to patients by establishing a fourth tier of drugs with a large copayment based on a substantial percentage of the cost of the drug. The number and cost of specialty drugs are expected to increase in the future. New approaches and reimbursement models are emerging to manage the high cost of new pharmaceuticals. Conclusion. Health-system pharmacists can improve drug safety and manage costs by collaborating with group purchasing organizations, establishing policies for brown bagging, and making efforts to reconcile drug therapy provided in different settings through traditional drug channels and specialty pharmacies or other restricted drug distribution systems.
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Costs; Drug distribution systems; Economics; Food and Drug Administration (U.S.); Health-benefit programs; Pharmacists, hospital; Pharmacy; Pharmacy, institutional, hospital; Regulations; Reimbursement; Risk management; Specialties; Toxicity Am J Health-Syst Pharm. 2009; 66(Suppl 7):S13-20 T he Food and Drug Administration (FDA) requires risk evaluation and mitigation strategies (REMS) for managing known or potential serious risks from certain drugs. 1, 2 These REMS are approaches established by FDA for working with pharmaceutical manufacturers to reduce risk from the use of a particular product. Although REMS vary based on the drug product, they have a common framework and components.
The number of drugs with REMS requirements is increasing, reflecting an increasing commitment of FDA to postmarketing surveillance. Restricted drug distribution systems may be a component of REMS, although REMS requirements do not necessarily include restricted drug distribution systems. The scope of restricted drug distribution systems extends beyond fulfillment of REMS requirements. Restricted drug distribution systems are entrepreneurial or business approaches to working with manufacturers, third-party payers, or pharmaceutical distributors. Restricted drug distribution systems may be established by the manufacturer, specialty pharmacies, wholesale distributors, or other specialty suppliers, including businesses seeking to provide services related to the distribution and administration of drugs with known serious risks that would otherwise be unavailable or those that are not commercially available and require sterile compounding. Restricted drug distribution systems provide an avenue for manufacturers to implement REMS for medications that require elements to ensure safe use.
Issues and concerns
In 2008, a task force was convened by the American Society of Health-System Pharmacists (ASHP) to identify key issues associated with Evaluate health care market trends and evolving business models for managing chronic diseases Consider size and complexity of hospitals and health systems and identify how patient medication needs are addressed in various settings (e.g., inpatient, outpatient, community, home care, long-term care) Identify evolving issues regarding continuity of care that result from increased use of these models and the devices used to administer many of these medications Identify challenges with policies and procedures, education, and communication and their impact on patient care and safety specialty drug delivery to patients through restricted drug distribution systems (Table 1) . The task force also identified "domains of concern" reflecting problems faced by patients, health care providers, and health facilities interacting with specialty pharmacies or other restricted drug distribution systems (Table 2) . Concerns about access to the drug product arise for both the patient and the pharmacy that needs to supply the drug to the patient. A major consideration for members of the task force is the labor involved in understanding and implementing the individual requirements of each specialty pharmacy and the investment of time by purchasing, pharmacy, and nursing staff. Educating nurses and other health care providers about requirements for obtaining and handling the drug also is a concern. Products that are administered by portable or implantable infusion devices pose further concerns and educational needs. Many problems related to patient access can be traced to a lack of sufficient education and knowledge about the operations of specialty pharmacies or other restricted drug distribution systems and about the use of portable or implantable infusion devices.
Most products supplied through specialty pharmacies and other restricted drug distribution systems initially are used in ambulatory care. Rules and regulations relating to product integrity come into play when a patient initiates drug therapy on an outpatient or ambulatory care basis and then requires hospitalization and continuation of drug therapy either in the inpatient setting or in an outpatient clinic using a drug product obtained outside the institution (a practice known as "brown bagging"). Table 3 summarizes problems that may arise. Continuity of care is a consideration in providing drug therapy when patients make the transition from one setting to another. Fragmentation of care provided in multiple settings can lead to errors and compromise patient outcomes.
Drug products supplied through specialty pharmacies and other restricted distribution systems are among the costliest available, with a large impact on the pharmacy budget. The task force considered the financial impact of specialty pharmacies and the need to ensure patient safety to be vital issues. Relationships among health care providers in different practice settings and the use of evidence-based practice also were concerns for members of the task force. A report from the task force, with recommended approaches for addressing these concerns and solving problems, will be published in the American Journal of Health-System Pharmacy.
Organizational issues
A culture of safety is essential for supporting the smooth integration of REMS into a health system. Fulfilling REMS requirements will present a challenge if administrators merely pay lip service to the need to ensure safety.
The ASHP Section of Pharmacy Informatics and Technology recently conducted a survey of the use of informatics and technology for various purposes in health systems, including fulfillment of REMS requirements. The survey was designed to ascertain the extent to which the pharmacy or hospital information system is being used to simplify the handling of products with REMS requirements. Ideally, the information system allows the tracking of patients receiving drugs with REMS requirements and suppliers of these drugs and provides information about REMS requirements and policies for fulfilling them by including these data in the Hospital policy; may or may not need additional contracts or registration to obtain drug; product integrity concern if medication is sent to patient; waste management for unused patient-specific medications; ability to charge for services provided Hospital policy; may or may not need additional contracts or registration to obtain drug; product integrity concern if medication is sent to patient; waste management for unused patient-specific medications; ability to charge for services provided drug master profile for each product with REMS requirements. The survey results suggest that more widespread use of informatics and technology to fulfill REMS requirements could help simplify the complex process involved. For example, incorporation of REMS requirements into the drug databases commonly used in pharmacy information systems (e.g., First DataBank, Medi-Span), with links to pharmaceutical manufacturer websites for reporting drug safety information, would facilitate greater use of informatics and technology in fulfilling REMS requirements.
Specialty pharmacies and suppliers
Health-system pharmacists often need to establish a working relationship with a specialty pharmacy or specialty distributor (e.g., wholesaler) to gain access to certain drug products with unique acquisition requirements and purchasing arrangements. These drug products are distributed through specialized channels outside traditional drug distribution mechanisms and include drugs with REMS requirements, drug products carved out from traditional distribution channels by manufacturers or wholesalers for various reasons, and fourth-tier drugs carved out by an insurer or payer with specific acquisition requirements for the patient to obtain coverage. The use of drug products provided by specialty pharmacies affects many aspects of patient care and presents logistical and financial challenges to the health care facility. Specialty pharmacies are usually under contract with third-party payers to provide a limited number of high-cost pharmaceutical products (e.g., injectable biological therapies, oral chemotherapy agents). 3 Healthsystem pharmacists often struggle with issues related to patient safety, institutional liability, and reimbursement for these products. Specialty pharmacy has been characterized in a variety of ways. According to one description, specialty pharmacy involves the handling of biotechnology-or genebased drug therapies that have one or more of the characteristics listed in Table 4 . 4 Several drug products supplied by specialty pharmacies are self-administered at home by infusion using implantable or external pumps after extensive patient education about the proper use of both the medication and the infusion device.
Specialty pharmacies are highly effective in marketing their services to payers. They claim to have greater knowledge of new clinical developments involving biotechnology and injectable products that affect payers' approaches to coverage and reimbursement than do health-system practitioners or ambulatory care pharmacies that oversee traditional drug distribution systems. Specialty pharmacies also claim to have greater expertise in managing certain products, disease states, and patient populations through utilization management protocols for injectable products than do practitioners in traditional drug distribution systems. These utilization management protocols ensure patients' adherence to therapy in the home care setting. The protocols could be expanded to address REMS requirements for collection of safety data. Specialty pharmacies typically handle drug products with short shelf lives and special storage requirements (usually refrigeration). Specialty pharmacies also claim to have a better understanding of Centers for Medicare & Medicaid Services (CMS) reimbursement policies and rates and how the policies and rates influence commercial payers than do pharmacists who manage traditional drug distribution systems. Simplified and standardized billing, coordinated networks for home drug delivery and infusion services, and complete data capture capabilities that facilitate comprehensive outcomes reporting and analysis (an attractive feature that helps fulfill REMS requirements) are among the possible services offered by specialty pharmacies. 5 As the number of drug products with REMS requirements has increased, wholesale distributors working with pharmaceutical manufacturers have reorganized and positioned themselves to function as specialty suppliers for these products outside traditional distribution channels. 6 Multiple new creative distribution channels for costly drug products have been established, and health-system pharmacists need to carefully consider and integrate these channels and carved-out products into their overall purchasing practices and strategies.
Group purchasing organizations can play a major role in coordinating specialty pharmacy and traditional drug purchasing contracts and distribution channels. Purchasing a biotechnology product through a specialty pharmacy on a cost-plusmarkup basis is substantially more expensive than purchasing the product from a traditional wholesaler at a discounted contract price (i.e., cost-minus basis), and this difference has important financial implications for health systems that should not be ignored. Carving out the priciest drug products from the drug spending pool at the wholesaler level has a negative impact on the contract rates offered and prepayment status for health systems.
Access to specialty pharmaceuticals and specialty distributors can be complex and time consuming for patients, health-system pharmacists, and other professionals in health systems. Patient safety, drug cost, drug product integrity, and continuity of care must be taken into consideration in a challenging environment characterized by conflict related to regulatory requirements, the high cost of pharmaceuticals, and the financial interests of third-party payers.
Not all drugs with REMS requirements need to be obtained through specialty pharmacies or restricted drug distribution systems, and not all drugs handled by these entities have REMS requirements. For example, natalizumab is available through a restricted drug distribution program that requires drug administration by authorized infusion centers, but it does not have REMS requirements. Clozapine has REMS requirements, but it is not supplied by specialty pharmacies. Infliximab, a drug administered by intravenous (i.v.) infusion and associated with serious infectious complications (including fatalities), is available through specialty pharmacies, but it has neither a restricted drug distribution system nor REMS requirements. Epoprostenol, a drug without REMS requirements, is handled only by certain distributors and administered i.v. for the treatment of pulmonary hypertension. 3 FDA required drug safety labeling changes for epoprostenol in 2008 because of an increased risk for hemorrhagic complications due to the drug's potent inhibition of platelet aggregation. 7 Understandably, the average health-system practitioner can be confused when it comes to knowing which rules and systems apply to which products.
Pharmaceutical reimbursement
The Medicare program as administered by CMS has three parts (A, B, and D). 8 Part A includes hospital inpatient and outpatient services, nursing home care, home health care, and hospice care. Reimbursement for covered medications, including some oral cancer chemotherapies, administered pursuant to a physician's care falls into Part B, as do physician services, medical supplies (e.g., durable medical equipment), and end-stage renal disease services (Table 5) . 9 Hospital outpatient services are administered through Part A and the Outpatient Prospective Payment System (OPPS). The Medicare prescription drug program falls into Part D and covers outpatient prescription drugs.
Reimbursable specialty drugs and biological products falling under Part Use for treatment of chronic or rare diseases Annual cost exceeding $5000 Administration by a route other than oral Product delivery to patients via mail or at home, possibly requiring special handling (e.g., refrigeration) Administration outside a hospital setting (e.g., physician's office, specialty clinic, or patient's home) Management outside the traditional outpatient prescription drug benefit Requirement for complex care, patient education, and continuous monitoring Table 4 . has not yet been assigned is 95% of the average wholesale price. 10 Passthrough payments may be available for new drugs and biologicals, and the basis for these payments is the average sales price (ASP) plus 6% (i.e., 106% of the ASP) or the wholesale acquisition cost (WAC) plus 6% (i.e., 106% of the WAC) until enough ASP data are available.
Characteristics of Therapies Handled by Specialty
In 2009, when the daily costs of specified covered outpatient drugs exceed the threshold of $60, ASP plus 4% (i.e., 104% of the ASP) is the basis for reimbursement when the products are administered in the hospital outpatient setting. 10 If daily drug costs fall below $60, the costs usually are packaged (i.e., bundled) into the payment for an ambulatory payment classification (a diagnostic classification analogous to an outpatient diagnosis-related group). The costs for "packaged products" are not reimbursed separately with the exception of antiemetic agents, which are reimbursed separately regardless of daily cost.
The Medicare Part D benefit covers only drugs that are classified as D drugs. Generally, Part D drugs include outpatient prescription drugs (i.e., drugs prescribed and dispensed for self-administration by the patient). They also include biological products, insulin, medical supplies associated with the injection of insulin (e.g., syringes, needles, alcohol swabs, sterile gauze), and certain vaccines not covered under Part A or B. Pneumococcal and influenza vaccines are covered by Part B. Hepatitis B vaccine is covered under Part B for individuals at high or intermediate risk; for all other individuals, it could be covered under Part D. All other currently available vaccines and future vaccines would be covered under Part D, but coverage could be subject to plan prior-authorization requirements for demonstrating medical necessity.
A new fourth tier of drugs has been added to prescription drug plans by some third-party payers and insurers in response to pressure from employers to reduce health care costs. Patients participating in these plans are required to pay 20-30% of the cost of certain high-cost drug therapies used to treat certain illnesses (e.g., cancer, rheumatoid arthritis, multiple sclerosis) instead of the flat copayments required for most drugs. 11 This approach shifts some of the cost of the most expensive drugs to patients. Some of these drug therapies cost as much as $15,000 per month, and the out-of-pocket cost of copayments for patients is substantial, although many plans have a cap (i.e., maximum).
Supply chain models
In recent years, the approach used for supply of certain high-cost pharmaceutical products has shifted from a traditional model to a specialty pharmacy model. The patient's source of prescription drug products and the roles of the hospital or health-system pharmacy and group purchasing organizations differ between a traditional and a specialty pharmacy supply chain model (Table  6 ). In a traditional model, patients obtain prescription drugs from an outpatient, retail, or mail order pharmacy. Hospital and other healthsystem pharmacies purchase drug products usually at a contract price from a traditional wholesaler on a volume, cost-minus basis. The group purchasing organization negotiates contract pricing for products and wholesaler agreements, and rebates usually apply.
By contrast, in the specialty pharmacy model, patients obtain prescription drugs from mail order or specialty pharmacies, with the payer often dictating a single source for each product. Drugs with REMS requirements are supplied by specialty pharmacies. Compounded drugs may be obtained from specialty pharmacies or a physician (e.g., an anesthesiologist who supplies opioid analgesics for epidural administration using an implantable pump). If a hospital or healthsystem pharmacy is involved in providing drug therapy to the patient, drug products usually are purchased from specialty suppliers on a costplus-markup basis without the benefit of contract prices, volume discounts, or rebates.
The shift from a traditional to a specialty pharmacy supply chain model has the potential to increase costs for health systems. Healthsystem pharmacists should establish Table 5 . 
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Challenges
Specialty drug products usually are not an issue for health-system pharmacists when the patient receives the drug at home, even if the patient visits a physician at a hospital outpatient clinic. However, a hospital policy for managing specialty drug products is needed for patients who hope to bring products obtained from specialty pharmacies for administration during visits to the hospital outpatient clinic or during an inpatient stay (Table 3) .
Health-system pharmacists may use one of two approaches to brown bagging of drugs with REMS requirements and other specialty drug products when the drug has been dispensed to an outpatient who seeks to have the product administered at a hospital outpatient clinic or as an inpatient. In a "pharmacy-centric" approach, policies and procedures prohibit brown bagging because of concerns about product integrity and institutional liability. The hospital dispenses the drug, even if it has already been dispensed by a specialty pharmacy on an outpatient basis and paid for by the insurance carrier. The hospital bears the cost of the drug, because reimbursement from third-party payers is not available for the same product a second time. To recoup this cost, patients are charged by the hospital for acquiring, dispensing, and administering the product. Providing these drug therapies without capturing these charges is not an option for the hospital using this approach.
In the past, when the number of specialty drug products and the volume of patients receiving these drugs were small and the cost of drugs was not as high, this pharmacy-centric approach had minimal financial impact on hospitals and health systems. However, because most specialty drug products now are very costly and larger numbers of patients are receiving them, this approach places a large burden on the hospital and in turn on the patient.
A "patient-centric" approach may be used to reduce the impact of specialty drug products on patients and hospitals. In such an approach, brown bagging is permitted in certain circumstances under strict protocol. In one approach, specialty drugs are brought to the hospital by the patient (i.e., they are not dispensed by the hospital), and the cost of the drug is 
Comparison of Traditional and Specialty Pharmacy Supply Chain Models
Variable
Traditional Model a REMS = risk evaluation and mitigation strategies. borne by the specialty pharmacy. In another, the arrangements are made for delivery of the specialty product directly to the hospital pharmacy, bypassing concerns about product integrity and storage conditions. In either case, the only hospital charge is for administration of the drug (i.e., there is no hospital charge for acquiring or dispensing the drug).
Specialty Pharmacy Model
The choice between a pharmacycentric and patient-centric approach to brown bagging often hinges on the institution's finances, tolerance for liability, and creativity in managing this new paradigm. Hospitals and health systems (e.g., medical centers with multiple separate facilities) may contemplate establishing their own specialty pharmacy because of the high cost of using outside specialty pharmacies. Key considerations in making this decision include whether the institution is eligible to participate in federal 340B drug discount plans and whether it has an outpatient department eligible to participate as a Medicare Part D sponsor and provider of medication therapy management services. A sufficiently large patient population is required for the business venture to be profitable. Services might be marketed to health systems in the local geographic area to ensure the fiscal viability of the venture. If the decision is made not to establish an in-house specialty pharmacy, the health system will need to determine whether to use a pharmacy-centric or patient-centric approach and make provisions for some degree of brown bagging.
Recent innovations in technology and therapeutics have increased the numbers of patients who selfadminister sterile compounded solutions by i.v. infusion using implantable or external pumps for the treatment of cancer, intractable pain, or chronic illnesses (e.g., pulmonary hypertension) in the home care setting. These patients and their caregivers have learned to use sophisticated drug administration devices and to assume considerable self-care responsibility, similar to the increase in patient responsibility for the management of diabetes mellitus that has taken place over the years. This selfcare capability helps patients remain at home, where their quality of life is better than it would be in a hospital. A wide variety of administration devices are available; in some cases, the language in the FDA-approved package insert specifies which specific infusion device must be used. This poses a potential challenge to nursing and pharmacy staff who may be less familiar with a particular administration device than are the patient and the patient's caregivers.
Some sterile products are commercially available, but others must be supplied by a compounding pharmacy (i.e., specialty pharmacy). The expiration dates established for sterile solutions compounded at some of these pharmacies extend beyond those that are customary and accepted in hospital-based compounding practices based on published stability data and USP Chapter 797. In some cases, the evidence supporting the expiration dates, credentials and accreditation status of the compounding pharmacy, safety of compounding practices, and integrity and labeling of compounded products may be questionable.
Hospitalization of a patient who has been self-administering sterile compounded solutions at home can be a challenge for health care providers, especially when the patient or caregivers do not understand why the patient's own solutions cannot be used. Hospital policies and procedures often prevent the patient from bringing such solutions from home, although provisions have not been made for therapies that are available only from compounding pharmacies. Delays in providing therapy and frustration among hospital staff may result from a lack of relevant institutional policies and procedures, uncertainty about the legitimacy of the compounding pharmacy supplying the sterile product, lack of education and familiarity with the features and operation of administration devices, and concerns about the need to provide care consistent with Joint Commission accreditation standards and CMS regulations pertaining to medication integrity and safety. The need to reconcile drug therapies provided in the outpatient and inpatient settings to meet Joint Commission national patient safety goals and the need to take a broad view in evaluating all of a patient's drug therapies instead of focusing on only one provide a strong argument for hospital policies and procedures precluding brown bagging.
Future of specialty pharmacy
Spending on specialty drugs amounted to approximately $54 billion in 2008 and is expected to nearly double to more than $99 billion by the end of 2010. 12 Specialty drugs account for 25-30% of the overall medical costs of a health plan. 13 Shifting costs to patients by classifying specialty drugs in a fourth tier represents an initial strategy for health plans coping with the high cost of new therapies. Patient copayments for fourth-tier specialty drugs can add up to nearly $60,000 a year for an individual receiving multiple products. 11 As additional high-cost therapies are introduced, health plans might consider the use of pay-for-performance and innovative manufacturer contract arrangements for managing the cost of these therapies. 14 An integrated approach is needed for managing the costs and ensuring the safety of specialty drug products. Components of such an approach might include pharmacy partnerships with specialty pharmacies and home infusion networks for timely product delivery, utilization management to ensure appropriate treatment initiation and adherence, coordination and standardization of electronic billing, and comprehensive data capture and outcomes analysis with online reporting capabilities. 5 The comparative effectiveness and overall value of specialty drug products are increasingly under scrutiny as health plans and other payers seeking to contain costs make their decisions about coverage. 15 Pharmaceutical manufacturers are devising innovative strategies to ensure that patients have access to their products and that reimbursement is available. Emerging reimbursement models for high-cost pharmaceuticals include risk-sharing agreements between manufacturers and payers, with onetime prepayments for drug therapies based on the overall value of therapy instead of payments for each dose administered.
In the past, many specialty drug products were administered at physician-operated infusion centers. However, rising costs and reductions in reimbursement have caused many of these centers to discontinue services, prompting hospitals and health systems to step in to fill the need for services. 16 Pharmacists in these settings view this as an opportunity to resolve problems with fragmented care by improving communication among physicians and pharmacists.
The survival of hospital-based infusion centers may depend on effective management of the reimbursement process by staff with expertise in reimbursement policies.
Conclusion
The changing paradigm in the supply chain for high-cost pharmaceuticals to permit brown bagging of drug products obtained through specialty pharmacies or other restricted drug distribution systems has important financial and safety implications for patients and health systems. Health-system pharmacists can improve drug safety and manage costs by collaborating with group purchasing organizations, establishing policies for brown bagging, and making efforts to reconcile drug therapy provided in different settings through traditional drug channels and specialty pharmacies or other restricted drug distribution systems.
